WealthBridge Capital Management LLC raised its holdings in Johnson & Johnson (NYSE: JNJ – Get Rating) by 77.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,456 shares of the company stock after buying an additional 2,383 shares during the period. WealthBridge Capital Management LLC’s holdings in Johnson & Johnson were worth $ 967,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Family CFO Inc purchased a new position in Johnson & Johnson in the fourth quarter valued at approximately $ 26,000. Steward Financial Group LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $ 34,000. Advocacy Wealth Management Services LLC grew its position in shares of Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company stock valued at $ 41,000 after buying an additional 67 shares during the last quarter. Iron Horse Wealth Management LLC raised its stake in Johnson & Johnson by 29.9% during the 4th quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company stock worth $ 45,000 after acquiring an additional 61 shares in the last quarter. Finally, Gibson Wealth Advisors LLC purchased a new stake in Johnson & Johnson in the fourth quarter valued at $ 49,000. 68.78% of the stock is owned by institutional investors.
In related news, insider William Hait sold 29,699 shares of the firm’s stock in a transaction that occurred on Thursday, April 21st. The stock was sold at an average price of $ 183.58, for a total value of $ 5,452,142.42. Following the completion of the transaction, the insider now directly owns 80,236 shares of the company stock, valued at approximately $ 14,729,724.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction on Friday, June 10th. The stock was sold at an average price of $ 173.00, for a total value of $ 6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares of the company stock, valued at $ 12,336,803. The disclosure for this sale can be found here. In the last three months, insiders sold 78,161 shares of company stock valued at $ 13,895,302. 0.35% of the stock is owned by corporate insiders.
Shares of NYSE: JNJ opened at $ 182.29 on Friday. Johnson & Johnson has a fifty-two week low of $ 155.72 and a fifty-two week high of $ 186.69. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. The firm’s 50-day simple moving average is $ 177.70 and its 200-day simple moving average is $ 173.40. The company has a market cap of $ 479.68 billion, a price-to-earnings ratio of 24.57, a PEG ratio of 3.61 and a beta of 0.66.
Johnson & Johnson (NYSE: JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, April 19th. The company reported $ 2.67 earnings per share for the quarter, beating analysts’ consensus estimates of $ 2.60 by $ 0.07. The company had revenue of $ 23.43 billion for the quarter, compared to analyst estimates of $ 23.62 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The firm’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $ 2.59 EPS. On average, research analysts forecast that Johnson & Johnson will post 10.23 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were given a $ 1.13 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $ 1.06. The ex-dividend date was Monday, May 23rd. This represents a $ 4.52 annualized dividend and a yield of 2.48%. Johnson & Johnson’s dividend payout ratio is presently 60.92%.
Several research firms have recently weighed in on JNJ. Citigroup reduced their target price on Johnson & Johnson from $ 210.00 to $ 205.00 in a report on Tuesday, May 17th. Credit Suisse Group increased their price target on Johnson & Johnson from $ 200.00 to $ 205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Morgan Stanley cut their target price on shares of Johnson & Johnson from $ 175.00 to $ 173.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 6th. The Goldman Sachs Group increased their price target on shares of Johnson & Johnson from $ 163.00 to $ 181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. Finally, Bank of America started coverage on shares of Johnson & Johnson in a report on Wednesday, March 2nd. They issued a “neutral” rating for the company. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $ 190.50.
Johnson & Johnson Profile: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.